Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safe, Non-Impairing Drug List Deemed Feasible By Panel Members

This article was originally published in The Tan Sheet

Executive Summary

Compiling a list of drugs that do not impair motor vehicle operators is possible, John Weiler, MD, University of Iowa, stated at a joint FDA/National Transportation Safety Board meeting Nov. 14

You may also be interested in...



Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L

A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports

Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L

A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports

Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L

A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel